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The genetic and physiological similarities between mice and humans have led to 
dedicate a remarkable attention on murine models in the biomedical research, due to 
their usefulness as models of human health and disease.  
Their employment in biomedical research has had a considerable impact after the 
advent of genetic engineering, which allowed creating genetically modified mice, in 
order to reproduce human diseases in the murine models. These animal models 
represent a powerful tool for the study of molecular and cellular mechanisms that 
underlie pathological conditions and, most importantly, a tool by which it is possible 
to test new therapies, allowing to improve the current treatments and minimizing 
any possible risks related to drugs. 
The main advantages of mice are their small size, little space and resources to 
maintain them, as well as their short gestation times (19-21 days), rapid 
development to adulthood (they reach sexual maturity at 5-6 weeks of age) and their 
high reproduction rate (Bryda, 2013). But the most advantage of the mice 
employment in the biomedical research is that they are a rich genetic resource: 
approximately 99% of mouse genes have a homologue in the human genome 
(Waterston RH et al, 2002).  
I developed my PhD career at the Institute for Genetic and Biomedical Research 
(IRGB), directed by Professor Francesco Cucca, who is a leader in the genetic 
dissection of complex diseases, especially autoimmune diseases.  
The aim of my PhD study is to identify molecular and cellular origins of both 
immunodeficiency and autoimmunity disease and understand the biological 
mechanisms that are implicated in immunosenescence by the analysis of a knock-out 
(KO) mouse, SH2B3 deficient mouse, as model of autoimmunity. The study 
includes the comparison of SH2B3 KO mouse with a group of human carriers of a 




specific genetic variant in the SH2B3 gene, also considering the impact of age on 
immune cell levels.  
Immunosenescence is defined as the decline of immune responses with age, 
characterized by dysregulated immune responses, leading to more severe 
consequences of bacterial and viral infections and reduced responses to vaccination 
(Montgomery RR and Shaw AC, 2015). Beginning with the sixth decade of life, the 
human immune system reduces the ability to protect against infections and cancer, 
but, conversely, inflammatory response gains in intensity and duration, rendering 
older individuals susceptible to tissue-damaging immunity and inflammatory disease 
(Weyand CM and Goronzy J, 2016). Paradoxically, the conditions of 
immunodeficiency and inappropriate immune response are present in aged 
population at the same time. 
In order to study mouse models for genes of particular interest in autoimmunity and 
immunosenescence, we combined different information available from the 
ProgeNIA/SardiNIA Project (a longitudinal study of genetics and epidemiology for 
ageing-related traits and diseases) and the Autoimmunity Case-Control Project [a 
case-control study of Multiple Sclerosis (MS) and Type 1 Diabetes (T1D) focused 
on ~10,000 individuals of the general population, where ~3,500 MS and ~2,000 
T1D patients are crossed to ~3,500 healthy controls, with at least three Sardinian 
grandparents], both conducted at IRGB. In particular, a recent study carried out in 
our Institute (Orrù V et al, 2013) demonstrated that specific immune cell levels and 
specific diseases are both associated with the same genetic signals, suggesting the 
involvement of those cells in disease predisposition. More specifically, the 
circulating levels of 95 immune cell populations, encompassing a total of 272 
immune cellular traits have been measured by flow cytometry in 2870 genetically 
characterized individuals. To identify the genetic variation accounting for the 
assessed traits, a sequencing-based Genome-Wide Association Study (GWAS) has 
been performed, assessing 8.2 million variants. 23 independent variants at 13 loci 




were found associated with at least one trait; notably, four loci overlapped with 
genetic variants known to be associated with autoimmune diseases (Orrù V et al, 
2013). 
Among the overlapping associations identified, we selected the missense mutation 
rs3184504 (C>T) in SH2B3 gene, which in humans increases the levels of helper T 
cells and lymphocytes (Orrù V et al, 2013) and it is also known to be associated with 
a variety of diseases including type 1 diabetes (Todd JA et al , 2007) (Plagnol et al, 
2011), chronic inflammatory diseases as ankylosing spondylitis, Crohn's disease, 
psoriasis, primary sclerosing cholangitis, ulcerative colitis (Ellinghaus D et al, 
2016), rheumatoid arthritis (Stahl EA, 2010), celiac disease (Trynka G et al, 2012), 
multiple sclerosis (International Multiple Sclerosis Genetics Consortium-IMSGC, 
2009), ischemic stroke and coronary artery disease (Dichgans M et al, 2014), 
increase of systolic and diastolic blood pressure (International Consortium for Blood 
Pressure Genome-Wide Association Studies, 2011) (Levy D et al, 2009). 
The non-synonymous SNP rs3184504 (C>T) is localized in the exon 3 of the SH2B3 
gene, (Chr.12q24) and leads to an amino acid change (Arg262Trp) in the pleckstrin 
homology domain of SH2B3 protein. The C allele (Arg) is conserved within closely 
related species and the risk allele T (Trp) is common in Europeans (46–52%), but 
virtually absent in African or Asian populations (<1% in HapMap data) 
(International Multiple Sclerosis Genetics Consortium-IMSGC, 2009). 
Despite its association with immune-related disorders, the genetic variant rs3184504 
presents evidence for recent positive selection in Europeans (Barreiro LB and 
Quintana-Murci L, 2010), including Sardinians. Positive selection refers to selection 
acting upon newly arisen or previously rare advantageous mutations that quickly 
increased in frequency due to specific driving force(s). As a consequence of this 
rapid change in frequency, haplotypes containing the favoured allele result in 
general more extended with respect to haplotypes containing the alternate allele, due 
to a lower impact of genetic recombination. Thus, extended haplotypes around a 











Effect SE P-value 
Lymphocytes	 3653	 0,464	 +0,154	 0,027	 9,39E-09	
T	Lymphocytes	CD3+	 3653	 0,470	 +0,147	 0,026	 2,65E-08	
T	helper	CD4+		 3652	 0,469	 +0,184	 0,027	 7,66E-12	
Central	Memory	CD4+		 3395	 0,471	 +0,161	 0,027	 2,99E-09	
Immunoglobulin	A	 5875	 0,473	 +0,119	 0,023	 2,43E-07	









The same immune traits were stratified into four age intervals: 18-40 years old, 41-
60 years old, 61-80 years old and over 80 years old. Notably, total lymphocytes, T 
helper lymphocytes, central memory CD4+ and platelets diminished with increasing 
age, whereas the IgA augmented, as shown in Table 2. 
 
 












Lymphocytes	 -2,569	 -4,166	 -7,370	 2,07E-13	 1,4E-25	 1,65E-20	
T	Lymphocytes	CD3+	 -2,293	 -4,117	 -7,334	 2,3E-18	 7,19E-43	 1,1E-34	
T	helper	CD4+		 -1,726	 -3,335	 -7,520	 8,63E-10	 2,78E-25	 9,97E-32	
Central	Memory	CD4+		 -0,238	 -0,903	 -2,416	 2,37E-02	 3,44E-14	 4,03E-24	
Immunoglobulin	A	 0,415	 0,698	 0,679	 1,55E-48	 5,63E-91	 9,08E-12	
Platelets	 -0,067	 -0,341	 -0,604	 2,27E-02	 3,39E-22	 1,57E-09	
	
Table	2.	Age	stratification	of	immune	trait	levels	in	the	SardiNIA	cohort.	Traits	indicated	in	the	
first	column	are	measured	 in	 the	SardiNIA	volunteers	at	age	 intervals	of	40-60,	60-80,	80-103	
years	and	compared	with	individuals	of	20-40	years.	Beta	indicates	the	effect	of	ageing	on	traits	
at	 each	 age	 range	 assessed,	 while	 P-values	 correspond	 to	 the	 statistical	 significance;	 the	




The effects of rs3184504-T on immune traits indicate a reduction of the SH2B3 
function resulting in lowered negative control of hematopoiesis, lymphopoiesis and 




megakaryopoiesis; for this reason, we believe that the SH2B3 KO mouse is an 
appropriate model to simulate the genetic variant effect in an experimental model, as 
it reproduces, even emphasizing the total lack of SH2B3, the reduction of gene 
function. The presence of an experimental animal model is a necessary investigation 
tool, by which it is possible to study in vivo the conditions and mechanisms that 
underlie the abovementioned autoimmune diseases, as well as the development of 
therapeutic strategies to prevent and improve them. 






SH2B3 (also named Lnk) is a member of the SH2-B (Src homology 2-B) protein 
family containing SH2B1 and SH2B2, originally named SH2-B and APS (adaptor 
protein with PH and SH2 domains), respectively (Devallièrea J and Charreaua B, 
2011). Adaptors are proteins lacking an enzymatic activity or other direct effector 
functions. They can be transmembrane proteins, as they reside in the cytoplasm 
under resting conditions and they can be recruited to the membrane upon activation. 
Alternatively, they can be localized in intracellular compartments such as the 
endoplasmic reticulum or lipid rafts. Regardless of their cellular localization, 
adaptor proteins possess an array of binding sites and modules that allow them to 
mediate specific protein–protein and protein–lipid interactions (Velazquez L, 2012). 
SH2B3 is structurally composed of a number of functional domains, including a 
carboxyl-terminal Src homology 2 (SH2) domain, which is essential for specific 
binding to phosphotyrosine residue, a pleckstrin homology (PH) domain, which 
recognizes phosphoinositides and controls protein translocation to the cell 
membrane, proline-rich regions, dimerization domain (DD) and several putative 
tyrosine phosphorylation motifs (Devallièrea J and Charreaua B, 2011). It is mainly 
expressed in hematopoietic cells and tissues, notably in hematopoietic stem cells 
(HSCs), in myeloid and lymphoid progenitors (Velazquez L, 2012) and in 
lymphocytes (Takaki S et al, 1997). 
The generation of mice and cell lines deficient for SH2B3 has helped to establish the 
physiological role for SH2B3 in the hematopoietic system. Two of the main 
signalling pathways where SH2B3 has proved to be a key negative regulator are the 
Stem Cell Factor (SCF)/Kit and the thrombopoietin (TPO)/Mpl pathways; these 
cytokines are crucial for the development, proliferation, migration and survival of 
progenitors (HSCs, hematopoietic and endothelial) and mature cells (mast cells and 
megakaryocytes/platelets) (Velazquez L, 2012). 




Stem cell factor (also known as SCF, KIT-ligand, KL, or steel factor) is a cytokine 
that plays critical roles in proliferation, survival, migration, and function of 
hematopoietic progenitor and mast cells through binding to Kit receptor (Simon C et 
al, 2008). 
Activation of Kit, a type III receptor tyrosine kinase, stimulates cellular responses 
such as the proliferation, survival, differentiation, chemotaxis and cell adhesion. 
When binding to its receptor Kit, SCF induces the dimerization or oligomerization 
of Kit, leading to the activation of its intrinsic kinase activity. The activated receptor 
becomes autophosphorylated at tyrosine residues that serve as docking sites for 
signal transduction molecules containing SH2 domains, including Grb2-associated 
binder 2 (Gab2) and phosphatidylinositol-3 kinase (PI3K); these recruit interacting 
molecules to nucleate signalling complexes to activate multiple pathways including 
PI3K, phospholipase C, protein kinase C, the Ras/mitogen-activated protein kinase 
(MAPK) cascade, and the Janus activated kinase/signal transducers and activators of 
transcription (JAK-STAT) pathway (Okayama Y and Kawakami T, 2006). Other 
phosphotyrosine (pY) residues serve as docking sites for Src homology 2 (SH2) 
domain–containing proteins such as SH2B3, in which the SH2 domain is critical for 
its association with Kit tyrosine kinase receptor, while the PH domain is 
indispensable for its localization in the plasma membrane (Takizawa H et al, 2006); 
by binding with Kit receptor, SH2B3 down-regulates SCF-induced proliferation 
with attenuation of MAPK and kinase signalling (Simon C et al, 2008).  
Velazquez and colleagues showed that SH2B3 deficient bone marrow-derived mast 
cells (BMMCs) displayed increased SCF-dependent migration compared with wild-
type cells, revealing SH2B3-mediated inhibitory function and demonstrating that 
SH2B3, through its binding to Kit tyrosine 567, negatively modulates specific SCF-
dependent signalling pathways involved in the proliferation and migration of 
primary hematopoietic cells (Simon C et al, 2008).  
Recent reports also indicated that SH2B3 negatively regulates the thrombopoietin 




(TPO) signalling in megakaryocytes (Tong W and Lodish HF, 2004) and the 
erythropoietin (EPO) signalling in erythroblasts (Tong W et al, 2005), in which 
upon receptor-ligand binding (TPO/Mpl and EPO/EPOr), JAK2 
autophosphorylation occurs, leading to activation of downstream signalling such 
STAT proteins; these proteins dimerize and translocate to the nucleus, where they 
activate transcription of target genes involved in a variety of cellular processes, 
including proliferation, differentiation, and apoptosis (Kisseleva T et al, 2002). 
             
          
        
    
         
        
          
         
        
    
         
       
     
  
      
        
    
     
      
         
       
           
    
       
      
    
   
    
        
       
      
      
      
        
      
   
      
     
 
      
To establish the role for SH2B3 in the hematopoietic system, the SH2B3 deficient 
mouse has been generated (Takaki S et al, 2000) (Velazquez L et al, 2002). 
Interestingly, this mouse model displays an accumulation of B lineage cells caused 
by overproduction of Pro-B cells and hematopoietic stem cells, which confirmed 
SH2B3 inhibitory role in Kit and Mpl signalling pathways. In particular, Takaki et 
al. generated a SH2B3 knock-out mouse and showed that SH2B3 gene constrains
production of B cells. Indeed the absence of SH2B3 resulted in a substantial
accumulation of B-lineage cells in the bone marrow (Pro-B, Pre-B and Immature B
cells) and in the spleen (Pre-B and B cells) of SH2B3 KO mice, whereas T cell 
development was unaffected. Also, serum levels of IgM, but not other
immunoglobulin isotypes, were substantially elevated in SH2B3 KO mice (Takaki S
et al, 2000). Later Velazquez group also generated a SH2B3 deficient mouse and 
showed, by histological analysis and flow cytometry, an abnormal accumulation of
erythroid cells, megakaryocytes, and B lymphocytes in different hematopoietic
compartments of SH2B3 deficient mice, indicating a defect in lymphoid and myeloid 
homeostasis. Importantly, they showed profound splenomegaly with excessive 
fibrosis; extensive extramedullary hematopoiesis; increase of megakaryocytes, 
erythrocytes and B220+ (also named CD45R+); rise of B220+ and megakaryocytes
in bone marrow; peripheral augmentation of white blood cell counts, lymphocytes, 
monocytes, neutrophils and circulating platelet levels in SH2B3 knock-out compared
with wild-type (WT) mice. Nevertheless, they did not observe any difference in T




cell lineages (Velazquez L et al , 2002). A year later, Takaki et al generated a 
transgenic mouse overexpressing SH2B3, resulting in both B and T cell reduction, in 
Pro-B cells reduction in bone marrow, and in Pro-T cells impairment in thymus, 
suggesting a function of SH2B3 in controlling also T lymphocyte production and 
function (Takaki S et al, 2003). 
Overall, these data showed that SH2B3 is an important negative regulator of 
lymphopoiesis, megakaryopoiesis, erythropoiesis and HSC proliferation by 
moderating growth factor and cytokine receptor-mediated signalling. Considering its 
crucial role in hematopoisesis and its involvement in autoimmunity, we believe that 
SH2B3 KO mouse requires further investigation to better understand its contribution 
in autoimmunity and its possible use as prognostic marker and therapeutic target. 
 






The main aims of this study are three: 
i) To compare the levels of specific immune traits in SH2B3 KO mice versus WT 
mice, 
ii) To compare the data obtained from mice with those obtained from humans, 
iii) To stratify mouse immune traits in five age ranges: 
! 2-3 months old that reproduce about 18 years old of man 
! 6-7 months old reproducing about 40 years old of man  
! 10-11 months old reproducing about 60 years old of man  
! 14-15 months old reproducing about 80 years old man  
! Over 18 months old that reproduce centenarian man.   
These aims are pivotal to better understand the cellular mechanisms in which the 
SH2B3 gene is involved and how these mechanisms change over time. 
 
The study includes the following assessments: 
! Analysis of a wide range of immune cell types in mice peripheral blood by 
flow cytometry; 
! Complete blood count (CBC) of peripheral leukocytes, lymphocytes, 
monocytes, granulocytes and platelets by Hematology Analyzer MS4; 
! Immunoglobulin Isotyping Assay to estimate IgA, IgE, IgG1, IgG2a, IgG2b, 
IgG3 and IgM in mice blood serum.




MATERIALS AND METHODS 
 
Mouse	model	
Knock-out mice (strain C57BL/6) characterized by insertion of neomycin 
phosphotransferase cassette (Neo) in the SH2B3 gene, were bought from the Riken 
Bio Resource Center (Japan). Wild-type mice (strain C57BL/6) were used as 




Genomic DNA was isolated from mice tails. Tails pieces were incubated at 55 °C 
for 3 hours with Proteinase K in Sodium Chloride-Tris-EDTA (STE) Buffer. The 
purification was performed with Isopropanol and 70% Ethanol. After isolation, the 
DNA was dissolved in ultra-pure water. 
  
Genotyping		
Genotypes were determined by polymerase chain reaction (PCR) from genomic 
DNA using a pair of primers on the SH2B3 gene  
(SH2B3/Fw 5’-TCAAAGCCCAAGCTCCAAGAG-3’;  
SH2B3/Rev 5’-ATCCATCGCCTGTGGCATGGAACC-3’)  
and a primer on the neomycin gene  
(Neo/Fw 5’-CAGGATCTCCTGTCATCTCACCTT-3’) 
to discriminate between WT and SH2B3 KO mice. 
PCR analysis was performed preparing a mix with H2O, 19,5 ul for each DNA 
sample (0,5 ul; sample concentration ≈ 1ug/ul) and reaction components; a PCR Kit 








PCR Buffer with MgCl2 10X  2,5 ul 
dNTP 2,5 mM:  0,5 ul 
Taq Polymerase:  0,2 ul 
 
The DNA primers (Sigma-Aldrich) were added into the mix as follows: 
 
primer SH2B3/Fw 60ng/ul:  0,6 ul 
primer SH2B3/Rev 60ng/ul:  0,6 ul 
primer Neo/Fw 60ng/ul:  0,6 ul 
 
The reaction was carried out in the Gene Amp PCR system 9600 thermocycler, at 
following reaction conditions: 
 






* repeated for 30 cycle 
 
The PCR products were visualised by agarose gel electrophoresis with SYBR® safe 
staining (Invitrogen) at UV trans-illuminator Uvitec. 
The WT band size is 1800 bp, whereas SH2B3 KO size is 600 bp. 
 
Flow	cytometry	measurements	
Blood was stained using fluorochrome-conjugated antibodies and analysed by flow 
cytometry (FACS Canto I, BD Biosciences). Flow cytometry is a technique used to 




measure physical and fluorescent characteristics of cells. In detail, cells are stained 
using fluorochrome-conjugated antibodies, suspended in a fluid and injected into the 
flow cytometer instrument. As soon as cells pass through the focused laser beam, 
they scatter the laser light in all direction. The light that scatters roughly in the same 
direction as the laser beam is called forward scatter (FSC); the light that scatters 
roughly perpendicular to the laser beam is called side scatter (SSC). FSC and SSC 
intensities are related to certain physical properties of cells: 
• FSC—indicates relative differences in the size of the cells or particles 
• SSC—indicates relative differences in the internal complexity or granularity of the 
cells or particles.  
Lasers also excites fluorescent antibodies used to stain cells and each antibody emits 
to specific wavelengths allowing one laser to excite many fluorochromes, each with 
a different wavelength emission, which is always longer than the excitation 
wavelength emanating by lasers. This scatter light and fluorescence is collected, 
filtered, then converted by the detectors into an electrical signal that can be 
processed by the electronics system and displayed as dot plots. The FACS Canto I 
analyser used for the present project is characterized has 2 lasers that emit at 488 nm 
(blue) and 633 nm (red) and detect 8 parameters: 6 fluorescence and 2 scatter 
parameters.  
To detect immune cell populations in the SH2B3 KO mouse model, 3 florescent-
antibody panels were designed (see below). All fluorochrome-conjugated antibodies 
were bought from Miltenyi Biotec. 
 
Panel 1: 
CD45-PE, mouse, clone 30-F11, for total leucocytes; 
CD45R-APC, mouse, clone RA3-6B2, for B cells; 
CD3e-APC-Vio770, mouse, clone 145-2C11, for T cells;  
CD4-PE-Vio770, mouse, clone GK1.5, for T helper lymphocyte; 




CD8a-FITC, mouse, clone 53-6.7, for cytotoxic T lymphocytes; 
 
Panel T: 
CD3e-APC-Vio770, mouse, clone 145-2C11, for T cell; 
CD4-PerCP-Vio700, mouse, clone GK1.5, for T helper lymphocytes; 
Anti-FoxP3 Vio515, mouse, clone REA788, for Regulatory T cells; 
CD8a-PE-Vio770, mouse, clone 53-6.7, for cytotoxic T lymphocytes; 
CD44-PE, mouse, clone IM7.8.1, with 
CD62L-APC, mouse, clone MEL14-H2.100, for distinction in Naive, Central 
Memory and Effector Memory T lymphocytes. 
 
Panel B: 
    
  
 
    




BD Trucount tubes and Lyse no Wash protocol was used to calculate blood 
leukocyte actual counts. In detail, 50 ul of whole blood collected in EDTA tubes 
were transferred to the BD Trucount tubes in reverse pipetting. Afterwards, the 
fluorochrome-conjugated antibodies mix - previously prepared using 2 ul of each 
fluorochrome-conjugated antibody - was added. The sample was incubated in the 
dark at room temperature (RT) for 15 minutes and then 1 ml of 1X BD FACS lysing 
solution was added and incubated at RT for 30 minutes to remove red blood cells. 
Samples were then acquired on the flow cytometer.  
CD45R-APC-Vio770, mouse, clone RA3-6B2;
CD19-FITC, mouse, clone 6D5;
Anti-IgD-APC, mouse, clone 11-26c.2a ;
Anti-IgM-PerCP-Vio700, mouse, clone X-54;
for distinction in B cells, Pro-B and Pre-B cells, Immature B cells, Early Mature 
B cells, Late Mature B cells and Plasmablast.





This panel was used to stain T lymphocytes from blood following Lyse-Wash 
protocol as manufacturer instruction. Briefly, whole peripheral blood (100 ul with 7 
ul of EDTA) was incubated with 2 ml of 1X BD FACS lysing solution for 15 
minutes at RT to remove red blood cells and then washed with 2 ml of wash solution 
BD FACSFlow. Each sample was resuspended in 100 ul of BD FACSFlow and 
stained with 2 ul of each fluorochrome-conjugated antibody previously mixed 
except anti-FoxP3-Vio515. Sample was incubated at 4°C in the dark for 30 minutes, 
then washed with 2 ml of BD FACSFlow, fixed with 1 ml of BD 
Fixation/permeabilization solution and permeabilized with 2 ml of BD 
Permeabilization Buffer 1X. 3ul of Anti-FoxP3-Vio515 were added to the sample 
and incubated at 4°C in the dark for 30 minutes. Finally, cells were washed, 
resuspended in 300 ul of FACSFlow and analysed by FACS Canto I. 
 
Panel B 
This panel was used to assess B cells from blood following Lyse-Wash protocol.  
Peripheral blood (100 ul with 7 ul f EDTA) was processed with 2 ml of 1X BD 
FACS lysing solution to remove red blood cells. The samples were then incubated at 
RT in the dark for 15 minutes, washed with 2 ml of BD FACSFlow and centrifuged 
to subsequently remove the supernatant. Each sample was resuspended in 100 ul of 
BD FACSFlow and 2 ul of each fluorochrome-conjugated antibody previously 
mixed was added to the sample. The sample was incubated at 4°C in the dark for 30 
minutes, then washed with 2 ml of BD FACSFlow. The sample was centrifuged at 
300 g for 5 minutes at 4°C. Supernatant was removed; the sample was resuspended 
in 300 ul of FACSFlow and analysed on FACS Canto I. 
 
Data were analysed with FACS-Diva software Version 6.1.3 (BD Biosciences). 
 





100 ul of mice blood were drawn and mixed with 7ul of EDTA. The sample was 
analysed by the Hematology Analyzer MS4 that detectes leukocytes, lymphocytes, 
monocytes, granulocytes and platelets as absolute count (cells/mm3 of blood) and as 




Immunoglobulins - IgA, IgE, IgG1, IgG2a, IgG2b, IgG3 and IgM - were measured 
in mice blood serum by ProcartaPlex Mouse Antibody Isotyping kit (Invitrogen) and 
the Bio-Plex MAGPIX multiplex Reader (Bio-Rad). Assay was performed as 
follows: 
Blood serum was separated from 50 ul of whole blood sample that clotted for 15-20 
minutes at RT; then centrifuged at 1,200 RPM for 15 minutes at RT. The serum 
fraction was collected and diluted 1:10,000-fold in Universal Assay Buffer (1X). 
Mouse Isotyping Standard Mix (Antigene Standard) was prepared and added to 
Antibody Magnetics Beads. 50 ul of Antibody Magnetic Beads were added to each 
well of a black 96-well Greiner Microplate, with 25 ul of Universal Assay Buffer 
(1X) and 25 ul of sample or controls. The plate was incubated at RT for 60 minutes, 
then 25 ul of Mouse Isotyping Detection Antibody Mix was added and incubated for 
30 minutes at RT; finally the beads were washed and resuspended in 120 ul of 
Reading Buffer. After 5 minutes, data were acquired by Bio-Plex MAGPIX 
multiplex Reader. 
The Bio-Plex MAGPIX multiplex Reader utilizes xMAP technology licensed from 
Luminex Corporation to permit the multiplexing of up to 100 different assays within 
a single sample. This technique involves 100 distinctly stained bead sets created by 
the use of two fluorescent dyes at distinct ratios. The use of different stained beads 
enables the simultaneous multiplex detection of many analytes in the same sample. 
In particular, color-coded beads, pre-coated with analyte-specific capture antibody 




for the molecule of interest, are added to the sample. Analyte-specific antibodies 
capture the analyte of interest. Afterwards, biotinylated detection antibodies specific 
to the analyte of interest are added and form an antibody-antigen sandwich. Finally, 
a fluorescent reporter dye label (Phycoerythrin (PE)-conjugated Streptavidin) is 
added to the sample. The beads are read on a dual-laser flow-based detection 
instrument where one laser classifies the bead and determines the analyte that is 
being detected and the second laser determines the magnitude of the PE-derived 
signal, which is proportional to the amount of bound analyte. 
 
Statistical	analysis		
All immunological traits analysed for both WT and SH2B3 KO mice are shown in 
Table 3 (see below). Statistical differences between means were calculated with 
parametric Student’s t-test and was confirmed by non-parametric Wilcoxon test, 











Leukocytes CD45+ - - 
B Lymphocytes (B Cells)  CD45R+ Lymphocytes Leukocytes 
T Lymphocytes (T Cells) CD3+ Lymphocytes Leukocytes 
T Helper Cells (Th) CD4+  T Lymphocytes  Lymphocytes 
Cytotoxic T Cells (CTL) CD8+ T Lymphocytes  Lymphocytes 
PANEL T 
T Lymphocytes (T Cells) CD3+ Lymphocytes Leukocytes  
T Helper Cells (Th) CD4+ T Lymphocytes  Lymphocytes 
Naive CD4+ T Cells CD62L+CD44-CD4+ T Helper Cells T Lymphocytes  
Central Memory (CM) CD4+ T Cells CD62L+CD44+CD4+ T Helper Cells T Lymphocytes  
Effector Memory (EM) CD4+ T Cells CD62L- CD44+ CD4+  T Helper Cells T Lymphocytes 










Regulatory T Cells (Tregs)  FoxP3+ CD4+ T Helper Cells T Lymphocytes 
Cytotoxic T Cells (CTL) CD8+ T Lymphocytes  Lymphocytes 
Naive CD8+ T Cells CD62L+ CD44- CD8+ Cytotoxic T Cells T Lymphocytes 
Central Memory (CM) CD8+ T Cells CD62L+ CD44+ CD8+ Cytotoxic T Cells T Lymphocytes 
Effector Memory (EM) CD8+ T Cells CD62L- CD44+ CD8+ Cytotoxic T Cells T Lymphocytes 
PANEL B  
B Lymphocytes (B Cells) CD19+CD45R+CD45R- Lymphocyte Leukocytes  
    CD19+CD45R+IgM-IgD- B Lymphocytes  Lymphocyte 
Immature/Transitional B Cells  CD19+CD45R+IgM+IgD- B Lymphocytes  Lymphocyte 
Early Mature B Cells  CD19+CD45R+IgM+IgD+ B Lymphocytes  Lymphocyte 
Late Mature B Cells  CD19+CD45R+IgM-IgD+ B Lymphocytes  Lymphocyte 
Plasmablast  CD19+ CD45R- B Lymphocytes  Lymphocyte 
C.B.C 
Leukocytes - Leukocytes - 
Lymphocytes - Leukocytes - 
Monocytes - Leukocytes - 
Granulocytes - Leukocytes - 
Platelets - Leukocytes - 
IMMUNOGLOBULIN ISOTYPING ASSAY 
IgA  - - - 
IgE  - - - 
IgG1  - - - 
IgG2a  - - - 
IgG2b  - - - 
IgG3  - - - 
IgM  - - - 
	





   Pro-B and Pre-B Cells






The main objective of the study is the comparison of the immune cell traits of the 
murine SH2B3 KO model with human traits, in particular with a group of 
individuals selected to carry a specific allelic variant positioned in the SH2B3 gene, 
the rs3184504-T variant; on the same cell traits the impact of age was also 
considered. In the human study, indeed, we noted that some immune trait levels 
were increased in blood of individuals carrying the genetic variant rs3184504-T. 
These traits include total lymphocytes, T lymphocytes CD3+, T helper lymphocytes 
CD4+, central memory CD4+, immunoglobulin A (IgA) and platelets  (Orrù V et al, 
2013, unpublished results, shown in Table 1); also we noted an ageing-related 
decline in the same cell populations, except for the IgA (Table 2). For this reason, 
we evaluated if the levels of the same trait could have an increase in SH2B3 KO 

















	 P-value	 P-value	 P-value	 P-value	
WT	 6/7	vs	2/3	 10/11	vs	2/3	 14/15	vs	2/3	 over	18	vs	2/3	
Leukocytes	 0,905	 0,022	 0,070	 0,258	
Lymphocytes	 0,693	 0,041	 0,852	 0,107	
Monocytes	 0,400	 2,69E-04	 5,51E-04	 2,52E-04	
Granulocytes	 0,464	 0,016	 3,12E-05	 1,34E-05	
Platelets	 0,950	 0,613	 0,002	 0,005	
B	Cells		 0,077	 0,010	 0,058	 0,029	
T	Cells	 0,009	 0,661	 0,785	 0,667	
Th	Cells		 0,236	 0,018	 0,370	 0,007	
CTL	 1,11E-04	 0,033	 0,290	 0,004	
SH2B3	KO	 6/7	vs	2/3	 10/11	vs	2/3	 14/15	vs	2/3	 over	18	vs	2/3	
Leukocytes	 0,300	 5,30E-05	 1,44E-09	 5,15E-05	
Lymphocytes	 0,037	 3,13E-06	 2,28E-10	 1,12E-04	
Monocytes	 0,869	 0,006	 2,57E-07	 7,24E-04	
Granulocytes	 0,282	 0,853	 5,30E-04	 3,70E-05	
Platelets	 0,159	 0,094	 0,021	 1,20E-04	
B	Cells		 9,26E-06	 0,014	 3,10E-05	 7,90E-05	
T	Cells	 0,137	 2,08E-04	 1,73E-09	 5,04E-04	
Th	Cells		 0,801	 3,80E-06	 8,21E-10	 1,78E-08	
















The alterations of blood immune cell populations detected in individuals carrying 
the non-synonymous allele rs3184504-T, located in the SH2B3 gene, is an example 
of genetic regulation of specific immune cell levels. Notably, this genetic variant is 
also predisposing for autoimmune diseases and other disorders (Orrù V et al, 2013). 
The analysis of the SH2B3 KO mouse confirmed a close link between the levels of 
blood immune cells and the SH2B3 protein. As expected, the silencing of SH2B3 in 
the KO mouse model has stronger and wider effect on the immune traits compare to 
the reduced function caused by the studied missense SH2B3 variant in humans. In 
the SH2B3 KO mouse, the silencing of the protein causes a total absence of its 
negative regulation of hematopoiesis, lymphopoiesis and megakaryopoiesis, as 
shown by a significant increase of monocytes, granulocytes, lymphocytes, and 
platelets (Figure 2). It suggests a role of SH2B3 already in blood cell precursors, 
such as common myeloid progenitor and common lymphoid progenitor. In humans, 
individuals carrying the rs3184504-T allele showed a significant increase of specific 
cell traits, especially T lymphocytes, T helper lymphocytes, central memory CD4+ 
cells, IgA and platelets; however, differently to what we found in the KO mouse, 
where both B cells and T cells (T helper and cytotoxic T cells) were increased 
(Figure 3), we did not observe any change in B cell levels in humans. It means that 
the human missense mutation has a cell-specific function, while the SH2B3 activity 
in mice is much broader and includes B cell regulation. Considering these 
observations, we believe that the KO model helps us to define the role of the SH2B3 
gene, but not to clarify the specific effect of the allelic variant rs3184504-T.  As the 
corresponding amino acid change occurs in the pleckstrin homology domain (Todd 
JA et al, 2007), which controls protein translocation to the cell membrane 
(Devallièrea J and Charreaua B, 2011), we believe that the substitution is pivotal in 




the cell-specificity of SH2B3 function. Moreover, different effects in human and 
mouse on B and T cells by SH2B3 could be explained by the fact that in humans T 
cells are higher compared to B cells, while the mouse strain C57BL/6, on which the 
SH2B3 KO mouse was created, is characterized by a greater amount of B cells 
compared to T cells (B cells: 67% ± standard deviation (SD); T helper cells: 13,3% 
±SD; CTLs: 7,7% ±SD of total lymphocytes) (Chen J and Harrison DE, 2002). 
Focusing on the impact of age on immune traits in the two mouse models, we 
observed that WT mice showed only a significant rise of monocytes and 
granulocytes during senescence, while CTLs increased only at 6-7 months, and then 
they decreased and remained stable. The other traits analysed, such as leukocytes, 
lymphocytes, B cells, T helper cells did not show significant changes with age 
(Figure 9B, 10, Table 4). Similarly, granulocytes and monocytes increased during 
senescence in the SH2B3 KO mouse, while differently from the WT model, T cells 
decreased and B cells increased during ageing (Figure 9-10, Table 4). It results in 
the fact that the increment of B cells in SH2B3 KO vs WT is stable and significant in 
the 5 age ranges assessed (Figure 8), while the increment of T cells in SH2B3 KO vs 
WT becomes not significant for helper and cytotoxic T cells at 10-11, 14-15 and 
over 18 months old (Figure 8, Figure 10, Table 4). Overall, SH2B3 KO mice are 
characterized by a strong dysregulation in the considered immune cell levels during 
ageing with some cells significantly increasing and other decreasing with ageing, 
indicating an age effect that, in conjunction with SH2B3 silencing, leads to a very 
important disequilibrium of immune populations, including platelets (Figure 9, 10, 
11). In humans these immune traits generally decrease with age (except for 
monocytes), whereas in the WT mouse the majority of them remain stable.  
Another interesting aspect is the role of SH2B3 in the immune cells maturation both 
in B and in T cells. During the development of B cells, from pro-B cells to 
plasmablasts, we noted an increased amount of pro-B, pre-B, immature and late 
mature B cells in SH2B3 KO compared to the WT mouse. The early mature B cell 




levels showed no significant difference between the two models, probably indicating 
a greater tendency of SH2B3 KO B cells to the rapid maturation compared to WT B 
cells (Figure 5). Similarly, in murine T cells, we observed a significant reduction of 
naive subsets (both CD4+ and CD8+) in the SH2B3 KO compared to the WT mouse, 
whereas the effector memory were increased in the KO mouse. This suggests that T 
cell maturation stages from naive to effector memory occur faster in absence of 
SH2B3 (Figure 6). Interestingly, central memory CD4+ lymphocytes, which in 
humans were increased in carriers of the rs3184504-T allele, did not increase in the 
SH2B3 KO mouse. This could happen because the central memory cells are much 
lower in mice compared to humans, alternatively, because central memory cells are 
mainly localized in lymphoid organs in mice (Bergmann B et al, 2013). 
The significant raise of B cells, especially plasmablasts (Figure 5) could also explain 
the increase of immunoglobulin sub-classes, such as IgA, IgE, IgG2a, IgG2b and 
IgM, in the SH2B3 KO mouse compared to WT (Figure 4). In contrast, in 
individuals carrying the rs3184504-T allele, we only observed an increase of IgA 
levels, while the others immunoglobulin classes were not affected. 
Our intent for the immediate future is a further stratification over time of the B and 
T cell subtypes, as well as of the immunoglobulin classes, which needs further 
number of mice to be studied. 
All cell populations detected so far have been analysed by mouse blood samples.  To 
have a more complete picture of the SH2B3 function in different districts of the 
organism, we are currently working on immune cells isolated from lymphoid organs 
such as bone marrow, thymus, spleen and lymph nodes. 
Moreover, to better understand the role of rs3184504, further future study will be 
focused on the generation of two humanised knock-in murine models carrying the 
two rs3184504 alleles. These models will be very useful to study the effect of the 
SNP in both blood and organs. The functional study of physiological and 
pathological changes mediated by rs3184504-T in animal models may suggest 




therapeutic strategies targeting SH2B3, where both the genetic background and the 
effect of age will be considered. 
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